IL297272A - influenza virus-like particles (vlps) - Google Patents
influenza virus-like particles (vlps)Info
- Publication number
- IL297272A IL297272A IL297272A IL29727222A IL297272A IL 297272 A IL297272 A IL 297272A IL 297272 A IL297272 A IL 297272A IL 29727222 A IL29727222 A IL 29727222A IL 297272 A IL297272 A IL 297272A
- Authority
- IL
- Israel
- Prior art keywords
- protein
- rna
- vlps
- group
- cells
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title claims description 7
- 239000002245 particle Substances 0.000 title claims 3
- 108090000623 proteins and genes Proteins 0.000 claims description 160
- 102000004169 proteins and genes Human genes 0.000 claims description 149
- 210000004027 cell Anatomy 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 210000004969 inflammatory cell Anatomy 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 15
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 15
- 229960005486 vaccine Drugs 0.000 claims 13
- 101710154606 Hemagglutinin Proteins 0.000 claims 8
- 102000005348 Neuraminidase Human genes 0.000 claims 8
- 108010006232 Neuraminidase Proteins 0.000 claims 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 8
- 101710176177 Protein A56 Proteins 0.000 claims 8
- 241000712461 unidentified influenza virus Species 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 244000052769 pathogen Species 0.000 claims 6
- 230000001717 pathogenic effect Effects 0.000 claims 6
- 102000011931 Nucleoproteins Human genes 0.000 claims 5
- 108010061100 Nucleoproteins Proteins 0.000 claims 5
- 239000000185 hemagglutinin Substances 0.000 claims 5
- 108020000999 Viral RNA Proteins 0.000 claims 4
- 241000287828 Gallus gallus Species 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 230000002457 bidirectional effect Effects 0.000 claims 2
- 241001493065 dsRNA viruses Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 210000003292 kidney cell Anatomy 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 230000001932 seasonal effect Effects 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 241000282709 Aotus trivirgatus Species 0.000 claims 1
- 241000282552 Chlorocebus aethiops Species 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000021597 necroptosis Effects 0.000 claims 1
- 229940070376 protein Drugs 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 135
- 102000051325 Glucagon Human genes 0.000 description 81
- 108060003199 Glucagon Proteins 0.000 description 81
- 229960004666 glucagon Drugs 0.000 description 79
- 150000001413 amino acids Chemical group 0.000 description 75
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 75
- 230000001052 transient effect Effects 0.000 description 75
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 49
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 49
- 238000012360 testing method Methods 0.000 description 47
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 42
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 38
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 35
- 102100040918 Pro-glucagon Human genes 0.000 description 35
- 230000000694 effects Effects 0.000 description 34
- 239000000556 agonist Substances 0.000 description 33
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 33
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 33
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 32
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 32
- 108010005794 dulaglutide Proteins 0.000 description 31
- 229960005175 dulaglutide Drugs 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 27
- 231100000240 steatosis hepatitis Toxicity 0.000 description 27
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 26
- 108010082126 Alanine transaminase Proteins 0.000 description 26
- 239000013642 negative control Substances 0.000 description 25
- 208000019425 cirrhosis of liver Diseases 0.000 description 22
- 239000002609 medium Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 206010012601 diabetes mellitus Diseases 0.000 description 20
- 238000000746 purification Methods 0.000 description 19
- 208000008589 Obesity Diseases 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 235000020824 obesity Nutrition 0.000 description 18
- 239000001488 sodium phosphate Substances 0.000 description 18
- 229910000162 sodium phosphate Inorganic materials 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 18
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 17
- 108010019598 Liraglutide Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 17
- 102000044159 Ubiquitin Human genes 0.000 description 16
- 108090000848 Ubiquitin Proteins 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 229960002701 liraglutide Drugs 0.000 description 16
- 210000005228 liver tissue Anatomy 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 14
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 14
- 208000004930 Fatty Liver Diseases 0.000 description 14
- 206010019708 Hepatic steatosis Diseases 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 14
- 108010068086 Polyubiquitin Proteins 0.000 description 14
- 102100037935 Polyubiquitin-C Human genes 0.000 description 14
- 239000005557 antagonist Substances 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 230000007863 steatosis Effects 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 208000010706 fatty liver disease Diseases 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000007882 cirrhosis Effects 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 201000007270 liver cancer Diseases 0.000 description 10
- 208000014018 liver neoplasm Diseases 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 102100020683 Beta-klotho Human genes 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 7
- 231100000234 hepatic damage Toxicity 0.000 description 7
- 230000008818 liver damage Effects 0.000 description 7
- 238000004020 luminiscence type Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 6
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000001593 cAMP accumulation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 5
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 5
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 5
- 108010093061 HLA-DPA1 antigen Proteins 0.000 description 5
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 5
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 102100027441 Nucleobindin-2 Human genes 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 235000021068 Western diet Nutrition 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- 238000007400 DNA extraction Methods 0.000 description 4
- 206010060891 General symptom Diseases 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 235000005956 Cosmos caudatus Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 3
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 3
- 101000684495 Homo sapiens Sentrin-specific protease 1 Proteins 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 102100023653 Sentrin-specific protease 1 Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 238000010876 biochemical test Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 2
- 102100040890 Glucagon receptor Human genes 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 2
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 2
- 102210049245 HLA-DQA1*05:01 Human genes 0.000 description 2
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 2
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 description 2
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000013622 capto Q Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940125542 dual agonist Drugs 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YEKUUBPJRPXMBM-PTCFZACGSA-N (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[2-(carboxymethylamino)-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(O)=O)C(O)=O YEKUUBPJRPXMBM-PTCFZACGSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- -1 Amino acid sequence GCG analogue SEQ ID NO: 2 GLP-1 analogue Chemical class 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000714933 Chryseobacterium nakagawai Species 0.000 description 1
- 102210012671 DPB1*01:01 Human genes 0.000 description 1
- 102210047286 DQB1*02:01 Human genes 0.000 description 1
- 102210010092 DQB1*03:01 Human genes 0.000 description 1
- 102210047287 DQB1*03:02 Human genes 0.000 description 1
- 102210042965 DQB1*06:02 Human genes 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 description 1
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 1
- 102220440888 HLA-DQA1*03:01 Human genes 0.000 description 1
- 102210049236 HLA-DRB1*03:01 Human genes 0.000 description 1
- 108010047214 HLA-DRB1*03:01 antigen Proteins 0.000 description 1
- 108010033222 HLA-DRB1*04 antigen Proteins 0.000 description 1
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 description 1
- 102210029654 HLA-DRB1*07:01 Human genes 0.000 description 1
- 102210059845 HLA-DRB1*15:01 Human genes 0.000 description 1
- 108010040960 HLA-DRB4 Chains Proteins 0.000 description 1
- 108010016996 HLA-DRB5 Chains Proteins 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 1
- 101710192923 Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 1
- 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 108091005205 cotadutide Proteins 0.000 description 1
- 229940121426 cotadutide Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010073571 gastric inhibitory polypeptide (1-39) Proteins 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229940118080 saxenda Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000013559 triple agonist Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169787.7A EP3896077A1 (en) | 2020-04-16 | 2020-04-16 | Influenza virus-like particles (vlps) |
| PCT/EP2021/055928 WO2021209199A1 (en) | 2020-04-16 | 2021-03-09 | Influenza virus-like particles (vlps) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297272A true IL297272A (en) | 2022-12-01 |
Family
ID=70292827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297272A IL297272A (en) | 2020-04-16 | 2021-03-09 | influenza virus-like particles (vlps) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230201336A1 (https=) |
| EP (2) | EP3896077A1 (https=) |
| JP (1) | JP2023526895A (https=) |
| KR (1) | KR20230004675A (https=) |
| CN (1) | CN115427430A (https=) |
| AU (1) | AU2021256266A1 (https=) |
| BR (1) | BR112022020997A2 (https=) |
| CA (1) | CA3172492A1 (https=) |
| IL (1) | IL297272A (https=) |
| MX (1) | MX2022012947A (https=) |
| WO (1) | WO2021209199A1 (https=) |
| ZA (1) | ZA202210419B (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2278621T5 (es) | 1999-07-14 | 2011-02-02 | Mount Sinai School Of Medicine Of New York University | Reconstrucción in vitro de virus arn segmentados de polaridad negativa. |
| US20070116717A1 (en) | 2005-08-01 | 2007-05-24 | Shneider Alexander M | Influenza vaccine compositions and methods |
| CN102373181B (zh) * | 2010-08-09 | 2014-06-11 | 中山大学 | 猪流感病毒和猪蓝耳病病毒混合病毒样颗粒、制备方法和应用 |
| US9150620B2 (en) * | 2012-04-18 | 2015-10-06 | National Tsing Hua University | Vaccine against multitypes of avian influenza viruses and uses thereof |
| HK1208355A1 (en) * | 2012-11-05 | 2016-03-04 | Georgia State University Research Foundation, Inc. | Universal influenza vaccine based on heterologous multiple m2e proteins |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US10494613B2 (en) * | 2015-08-28 | 2019-12-03 | Wisconsin Alumni Research Foundation (Warf) | Generation of infectious influenza viruses from virus-like particles |
| EP3814509A4 (en) | 2018-06-27 | 2022-07-27 | Medicago Inc. | INFLUENCE VIRUS HEMAGGLUTININ MUTANTS |
| WO2020014656A1 (en) | 2018-07-13 | 2020-01-16 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof |
-
2020
- 2020-04-16 EP EP20169787.7A patent/EP3896077A1/en not_active Ceased
-
2021
- 2021-03-09 MX MX2022012947A patent/MX2022012947A/es unknown
- 2021-03-09 AU AU2021256266A patent/AU2021256266A1/en active Pending
- 2021-03-09 CN CN202180028559.3A patent/CN115427430A/zh active Pending
- 2021-03-09 JP JP2022563230A patent/JP2023526895A/ja active Pending
- 2021-03-09 US US17/996,300 patent/US20230201336A1/en active Pending
- 2021-03-09 KR KR1020227040161A patent/KR20230004675A/ko active Pending
- 2021-03-09 BR BR112022020997A patent/BR112022020997A2/pt unknown
- 2021-03-09 IL IL297272A patent/IL297272A/en unknown
- 2021-03-09 WO PCT/EP2021/055928 patent/WO2021209199A1/en not_active Ceased
- 2021-03-09 CA CA3172492A patent/CA3172492A1/en active Pending
- 2021-03-09 EP EP21709710.4A patent/EP4136094A1/en active Pending
-
2022
- 2022-09-20 ZA ZA2022/10419A patent/ZA202210419B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022020997A2 (pt) | 2022-12-06 |
| JP2023526895A (ja) | 2023-06-26 |
| AU2021256266A1 (en) | 2022-10-13 |
| MX2022012947A (es) | 2022-11-14 |
| EP4136094A1 (en) | 2023-02-22 |
| EP3896077A1 (en) | 2021-10-20 |
| US20230201336A1 (en) | 2023-06-29 |
| ZA202210419B (en) | 2023-05-31 |
| KR20230004675A (ko) | 2023-01-06 |
| WO2021209199A1 (en) | 2021-10-21 |
| CA3172492A1 (en) | 2021-10-21 |
| CN115427430A (zh) | 2022-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6870017B2 (ja) | インフルエンザウイルス変異体およびその使用 | |
| JP2022066209A (ja) | Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス | |
| US8486890B2 (en) | Amylin derivatives | |
| US7527967B2 (en) | Recombinant baculovirus and virus-like particle | |
| EP2674486A1 (en) | Influenza B viruses having alterations in the hemaglutinin polypeptide | |
| JP2019187419A (ja) | グルカゴン類似体 | |
| TW202118775A (zh) | 升糖素及glp-1共激動劑化合物 | |
| WO2019119673A1 (zh) | 一种双基因修饰的干细胞及其用途 | |
| JP2015502353A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| US9878032B2 (en) | Attenuated influenza vaccines and uses thereof | |
| CN114213548B (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| JP2016525889A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| EP2073818A2 (en) | Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors | |
| KR102738851B1 (ko) | 신규한 단백질 결합체, 및 이의 비알콜성 지방간염, 비만 및 당뇨 질환의 예방 또는 치료 용도 | |
| IL297272A (en) | influenza virus-like particles (vlps) | |
| CN108610409A (zh) | Etv5在制备预防或治疗肥胖症及相关代谢性疾病药物中的应用 | |
| RU2822001C1 (ru) | Новый белковый конъюгат и его применение для профилактики или лечения неалкогольного стеатогепатита, ожирения и диабета | |
| WO2011011733A2 (en) | Factor replacement therapy | |
| CN113975299B (zh) | 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用 | |
| HK40079238A (en) | Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes | |
| CN107998382B (zh) | 含otu功能域去泛素化酶7b在制备治疗脂肪肝及相关疾病药物中的应用 | |
| EP4556017A1 (en) | Hepatitis b virus receptor oatp and use thereof | |
| Sadler | Evaluation of a single cycle influenza virus as a candidate vaccine | |
| CA2535127C (en) | H3 equine influenza a virus | |
| KR20130121804A (ko) | Ｈ3 말 인플루엔자 ａ 바이러스 |